Skip to main content
. 2018 Feb 5;18:130. doi: 10.1186/s12885-018-4016-3

Fig. 3.

Fig. 3

Survival outcomes for stage II patients with molecular classification by the 31-gene expression profile test. a Recurrence-free, b distant metastasis-free, and c melanoma-specific survival rates for stage II cases (n = 93) using binary classification as indicated by Kaplan-Meier analysis. d Recurrence-free, e distant metastasis-free, and f melanoma-specific survival rates for stage II cases using molecular subclassification. Five-year survival rates, number of specified events, 95% confidence intervals, and percentages of each class experiencing an event are listed in the tables below the curves